jane
e
syke
mark
g
papich
w
key
point
antivir
drug
avail
treatment
canin
felin
viral
infect
nucleosid
analogu
greatest
activ
herpesviru
retroviru
infect
antivir
drug
also
affect
function
host
cell
machineri
consider
potenti
toxic
antivir
drug
wide
use
human
medicin
treatment
herpesviru
hiv
viral
infect
much
less
known
medic
dog
cat
diseas
dog
cat
efficaci
demonstr
import
differ
human
anim
viru
infect
one
never
assum
antivir
agent
use
peopl
use
anim
unless
proof
safeti
efficaci
antivir
drug
use
treat
felin
herpesvir
infect
includ
famciclovir
idoxuridin
cidofovir
zidovudin
antiretrovir
drug
demonstr
efficaci
treatment
cat
primarili
fiv
infect
antivir
drug
act
synergist
immunomodul
immunomodul
includ
microbi
product
plantderiv
immunomodul
natur
occur
mammalian
protein
glucocorticoid
synthet
compound
pentoxifyllin
opioid
effect
mani
drug
outcom
dog
cat
infecti
diseas
fulli
evalu
use
larg
prospect
random
mask
control
clinic
trial
parenter
use
natur
recombin
human
protein
immunomodul
dog
cat
may
result
format
neutral
antibodi
week
treatment
crossreact
endogen
protein
purpos
chapter
describ
mechan
action
spectrum
activ
advers
effect
major
antivir
immunomodulatori
drug
exhibit
util
potenti
treatment
companion
anim
infecti
diseas
enorm
number
differ
compound
consid
evalu
vitro
vivo
variabl
success
current
use
treatment
dog
cat
natur
occur
infect
show
consider
promis
futur
evalu
control
clinic
trial
discuss
chapter
antivir
agent
interfer
virusspecif
event
replic
includ
viral
attach
uncoat
assembl
virusdirect
macromolecular
synthesi
result
antivir
agent
typic
restrict
spectrum
activ
contrast
antibacteri
drug
antivir
drug
also
affect
function
host
cell
machineri
thu
antivir
drug
greater
risk
toxic
addit
acut
toxic
marrow
suppress
mani
antivir
agent
immunosuppress
carcinogen
teratogen
mani
given
topic
order
minim
system
toxic
antivir
agent
like
effect
intact
host
immun
respons
present
combin
antivir
drug
differ
mechan
action
combin
antivir
immunomodulatori
drug
increasingli
use
treat
human
viral
infect
especi
hiv
infect
associ
decreas
toxic
reduct
select
drugresist
mutant
although
antivir
drug
use
treat
small
anim
origin
develop
treatment
human
viral
infect
applic
drug
treat
viral
infect
small
anim
proven
straightforward
relat
differ
composit
human
companion
anim
virus
affect
suscept
inactiv
antivir
drug
problem
relat
toxic
human
antivir
drug
dog
cat
antivir
drug
classifi
base
spectrum
activ
ie
famili
virus
inhibit
mode
action
antivir
drug
use
small
anim
medicin
primarili
effect
herpesvirus
retrovirus
nucleosid
analogu
nucleosid
analogu
resembl
host
nucleosid
nitrogen
base
attach
sugar
molecul
use
build
block
format
dna
rna
figur
use
nucleosid
analogu
virus
replic
lead
format
abnorm
nucleic
acid
termin
nucleic
acid
synthesi
latent
viral
infect
affect
replic
latent
viru
suspend
howev
reactiv
infect
reduc
frequenc
prevent
exampl
nucleosid
analogu
spectrum
activ
shown
figur
tabl
antivir
drug
use
clinic
veterinari
medicin
includ
amino
acid
llysin
neuraminidas
inhibitor
oseltamivir
valu
treatment
small
inhibitori
rna
molecul
viral
infect
small
anim
also
investig
standard
antivir
treatment
herpesvir
infect
human
patient
nucleosid
analogu
acyclovir
penciclovir
prodrug
valacyclovir
famciclovir
respect
drug
activ
herpesvir
enzym
thymidin
kinas
tk
phosphoryl
monophosph
form
host
cell
enzym
phosphoryl
drug
triphosph
form
concentr
virusinfect
cell
interfer
viral
dna
replic
via
inhibit
viral
dna
polymeras
enzym
dna
polymeras
differ
herpesvirus
inhibit
vari
degre
acyclovir
triphosph
herpesvir
infect
equal
suscept
drug
resist
result
reduc
viral
tk
activ
alter
viral
tk
alter
viral
dna
polymeras
antiherpesvir
drug
cidofovir
idoxuridin
trifluridin
vidarabin
depend
viral
tk
phosphoryl
greater
host
cell
toxic
small
anim
medicin
four
drug
use
topic
treat
ocular
felin
herpesvir
infect
acyclovir
synthet
analogu
purin
nucleosid
deoxyguanosin
see
figur
human
patient
acyclovir
wide
use
treat
herp
simplex
varicellazost
viru
infect
small
anim
medicin
acyclovir
primarili
use
treat
felin
infect
although
much
lower
suscept
drug
compar
human
herpesvirus
acyclovir
also
use
treat
canin
infect
puppi
see
chapter
nucleosid
analogu
trifluridin
idoxuridin
cidofovir
ganciclovir
penciclovir
show
much
greater
activ
acyclovir
vitro
topic
acyclovir
use
limit
success
treat
felin
herpet
dermat
kerat
topic
treatment
requir
frequent
time
day
applic
benefici
effect
oral
bioavail
acyclovir
low
cat
high
dose
requir
achiev
adequ
serum
drug
concentr
valacyclovir
prodrug
acyclovir
rapidli
convert
acyclovir
firstpass
effect
oral
administr
administr
prodrug
result
improv
oral
bioavail
acyclovir
unfortun
administr
high
dose
acyclovir
valacyclovir
cat
result
signific
toxic
includ
myelosuppress
renal
tubular
necrosi
hepat
necrosi
without
effect
suppress
viral
replic
thu
use
system
acyclovir
valacyclovir
treat
cat
herpesviru
infect
recommend
antivir
drug
use
treat
small
anim
patient
penciclovir
famciclovir
shown
greatest
promis
penciclovir
anoth
guanosin
analogu
see
figur
present
much
higher
concentr
longer
durat
cell
acyclovir
permit
less
frequent
dose
human
prodrug
famciclovir
well
absorb
oral
rapidli
convert
penciclovir
lead
increas
oral
bioavail
penciclovir
drug
elimin
unchang
urin
dose
reduct
may
requir
anim
decreas
kidney
function
human
patient
concurr
administr
food
decreas
peak
plasma
concentr
without
affect
overal
bioavail
human
herp
simplex
viru
herp
zoster
infect
famciclovir
effect
acyclovir
contrast
penciclovir
thu
famciclovir
shown
potent
inhibitor
replic
case
acyclovir
penciclovirresist
mutant
alter
tk
enzym
describ
administr
famciclovir
cat
dosag
compar
use
speci
result
much
lower
plasma
concentr
longer
time
develop
peak
plasma
concentr
penciclovir
compar
anim
speci
suggest
alter
absorpt
metabol
famciclovir
cat
high
dose
famciclovir
requir
achiev
adequ
plasma
drug
concentr
nevertheless
famciclovir
well
toler
administ
oral
cat
dose
produc
clinic
respons
treatment
cat
experiment
induc
conjunct
famciclovir
mgkg
po
day
result
lower
clinic
patholog
diseas
score
decreas
viral
shed
compar
placebotr
cat
clinic
respons
also
occur
natur
infect
cat
acut
chronic
manifest
diseas
neglig
advers
effect
satur
metabol
famciclovir
penciclovir
equival
serum
tear
penciclovir
concentr
achiev
cat
mgkg
po
famciclovir
mgkg
po
consid
equal
efficaci
clinic
improv
often
occur
within
week
treatment
ganciclovir
resembl
acyclovir
except
addit
hydroxymethyl
group
acycl
side
chain
see
figur
human
patient
ganciclovir
wide
use
specif
treatment
human
cytomegaloviru
infect
life
threaten
immunocompromis
cytomegalovirus
system
administr
ganciclovir
human
patient
associ
high
preval
advers
drug
reaction
especi
cytopenia
central
nervou
system
cn
sign
use
ganciclovir
limit
patient
lifethreaten
sightthreaten
infect
topic
ophthalm
gel
formul
ganciclovir
avail
treatment
kerat
caus
herp
simplex
ganciclovir
highli
inhibitori
replic
vitro
pharmacokinet
safeti
efficaci
studi
cat
yet
perform
topic
ganciclovir
hold
promis
treatment
felin
ocular
herpesvir
infect
cidofovir
nucleotid
analogu
deoxycytidin
monophosph
drug
alreadi
monophosph
group
metabol
activ
diphosph
form
host
cellular
enzym
depend
viral
tk
use
treat
acyclovirand
penciclovirresist
infect
human
patient
cidofovir
primarili
use
treat
cytomegaloviru
retin
cidofovir
also
efficaci
dna
viru
infect
poxviru
papillomaviru
infect
use
topic
cream
treat
viral
wart
peopl
oral
bioavail
cidofovir
extrem
low
alway
administ
intraven
intravitr
topic
cidofovir
prolong
intracellular
halflif
enabl
infrequ
parenter
dose
regimen
human
patient
weekli
everi
week
mainten
therapi
like
ganciclovir
cidofovir
highli
activ
vitro
twicedaili
administr
cidofovir
ophthalm
solut
significantli
decreas
viral
shed
sever
clinic
diseas
cat
experiment
induc
ocular
infect
tabl
local
irrit
scar
nasolacrim
duct
report
topic
administr
cidofovir
human
rabbit
keratoconjunct
idoxuridin
trifluridin
halogen
thymidin
analogu
interfer
replic
vitro
although
potent
inhibitor
herp
simplex
viru
replic
use
treat
herpesvir
kerat
human
cat
drug
highli
toxic
given
system
host
cell
viral
dna
synthesi
equal
affect
frequent
topic
applic
requir
five
six
time
daili
prolong
use
caus
corneal
irrit
ulcer
trifluridin
better
corneal
penetr
idoxuridin
avail
ophthalm
solut
unfortun
trifluridin
expens
ocular
administr
trifluridin
often
extrem
irrit
cat
contrast
topic
idoxuridin
administr
gener
well
toler
vidarabin
adenosin
analogu
phosphoryl
host
cellular
enzym
vidarabin
triphosph
interfer
dna
synthesi
viru
host
cell
effect
idoxuridineresist
herpesvir
strain
mechan
action
differ
idoxuridin
reportedli
well
toler
cat
administ
five
six
time
daili
cat
ophthalm
ointment
lysin
amino
acid
interfer
herpesvir
replic
poorli
understood
mechan
antagon
arginin
may
somehow
involv
high
lysinetoarginin
ratio
appear
import
efficaci
howev
arginin
also
shown
interfer
replic
herp
simplex
viru
vitro
lysin
shown
efficaci
administ
tablet
cat
conjunct
anoth
studi
reduc
shed
reactiv
viru
latent
infect
cat
administ
tablet
cat
shelter
reduct
upper
respiratori
tract
diseas
concern
stress
tablet
administr
may
contribut
diseas
cat
howev
two
studi
dietari
supplement
lysin
effect
manag
upper
respiratori
tract
diseas
shelter
fact
cat
receiv
lysinesuppl
diet
sever
diseas
frequent
viral
shed
cat
receiv
nonsuppl
ration
despit
increas
plasma
lysin
concentr
lysinesuppl
diet
affect
plasma
arginin
concentr
alter
arginin
level
appear
contribut
increas
sever
diseas
antivir
drug
use
treat
cat
retroviru
infect
nucleosid
analogu
inhibit
dna
polymeras
function
retrovir
revers
transcriptas
rt
enzym
unfortun
mani
drug
use
treatment
hiv
infect
proteas
inhibitor
effect
treatment
felin
retroviru
infect
act
hiv
enzym
antiretrovir
shown
benefit
natur
infect
cat
zidovudin
azt
time
write
integras
inhibitor
known
raltegravir
shown
earli
promis
treatment
felv
infect
vitro
vivo
mani
drug
activ
felin
retrovirus
vitro
ribavirin
adefovir
pmea
toxic
given
cat
limit
use
practic
zidovudin
azidothymidin
azt
retrovir
thymidin
analogu
one
first
drug
shown
effect
hiv
insid
host
cell
convert
activ
triphosph
form
azt
inhibit
replic
fiv
reduc
plasma
viral
load
improv
stomat
increas
ratio
cat
natur
infect
fiv
fiv
isol
resist
result
mutat
rt
enzym
although
azt
activ
felv
vitro
compar
fivinfect
cat
perform
well
treatment
natur
infect
sick
cat
chronic
felv
infect
nevertheless
improv
stomat
reduc
antigenemia
reduct
develop
lymphoma
report
studi
natur
experiment
felvinfect
cat
treat
azt
azt
avail
mgml
syrup
mgml
inject
good
oral
bioavail
well
distribut
tissu
includ
cn
metabol
inact
form
liver
excret
kidney
dosag
reduct
recommend
cat
renal
failur
unfortun
cat
treat
azt
develop
doserel
hematolog
advers
effect
commonli
nonregen
anemia
neutropenia
cbc
must
monitor
treatment
advers
effect
may
confus
retrovirusinduc
cytopenia
human
patient
hiv
infect
cytopenia
like
occur
diseas
advanc
fozivudin
thioether
lipidzidovudin
conjug
undergo
intracellular
cleavag
zidovudin
monophosph
subsequ
phosphoryl
activ
triphosph
form
cleavag
preferenti
occur
lymphocyt
monocyt
compar
rbc
marrow
stem
cell
hematolog
toxic
less
like
occur
fozivudin
reduc
viremia
cat
experiment
infect
fiv
without
signific
advers
effect
studi
requir
evalu
drug
treatment
chronic
fiv
felv
infect
cat
lamivudin
cytidin
analogu
synergist
combin
azt
treatment
hiv
infect
combin
common
use
human
medicin
prevent
fiv
infect
given
cat
shortli
experiment
inocul
appear
benefici
treatment
cat
chronic
fiv
infect
addit
sever
hematolog
advers
effect
fever
occur
cat
raltegravir
inhibit
retrovir
integras
enzym
integras
incorpor
transcrib
viral
dna
host
chromosom
human
patient
raltegravir
approv
treatment
hiv
infect
use
combin
antiretrovir
drug
although
expens
raltegravir
shown
great
promis
treatment
felv
infect
vitro
also
vivo
drug
shown
promis
vitro
treatment
felv
infect
evid
toxic
cell
cultur
nucleosid
analogu
tenofovir
decitabin
gemcitabin
tenofovir
use
part
combin
therapi
treat
hiv
infect
administ
prodrug
decitabin
gemcitabin
cytidin
analogu
use
human
patient
treat
myelodysplast
syndrom
carcinoma
respect
use
combin
gemcitabin
carboplatin
treat
carcinoma
cat
report
cytopenia
gastrointestin
toxic
occur
cat
plerixafor
bicyclam
deriv
select
block
chemokin
receptor
receptor
use
fiv
enter
cell
see
chapter
placebocontrol
mask
clinic
trial
administr
plerixafor
cat
fiv
infect
week
reduc
provir
load
lead
improv
clinic
immunolog
variabl
main
drug
use
human
medicin
treat
influenza
viru
infect
neuraminidas
inhibitor
oseltamivir
zanamivir
tricycl
amin
amantadin
rimantadin
inhibit
ion
channel
protein
present
influenza
virus
figur
oseltamivir
use
great
extent
small
anim
amantadin
also
antagonist
effect
nmda
nmethyldaspart
receptor
use
treat
osteoarthr
anim
combin
drug
oseltamivir
oseltamivir
tamiflu
prodrug
oseltamivir
carboxyl
potent
inhibitor
influenza
viru
neuraminidas
oseltamivir
develop
poor
oral
bioavail
zanamivir
neuraminidas
inhibitor
structur
similar
neuraminidas
surfac
glycoprotein
influenza
influenza
b
virus
see
figur
viral
neuraminidas
cleav
sialic
acid
residu
surfac
infect
cell
allow
new
viru
particl
releas
host
cell
also
prevent
aggreg
viru
particl
releas
facilit
spread
viru
mucu
respiratori
tract
cleav
sialic
acid
residu
mucin
human
dog
oseltamivir
high
oral
bioavail
esteras
enzym
liver
convert
oseltamivir
activ
form
well
distribut
bodi
fluid
includ
surfac
epitheli
cell
throughout
upper
lower
respiratori
tract
elimin
drug
reli
renal
excret
drug
well
toler
human
gastrointestin
sign
frequent
report
advers
effect
preval
resist
oseltamivir
among
influenza
viru
isol
gener
low
highlevel
resist
result
mutat
viral
neuraminidas
neuraminidas
inhibitor
could
play
critic
role
prevent
mortal
human
influenza
viru
pandem
strategi
minim
select
resist
mutant
import
center
diseas
control
prevent
recommend
priorit
antivir
treatment
human
patient
risk
complic
influenza
young
old
oseltamivir
use
treat
canin
parvoviru
cpv
enter
puppi
anecdot
report
improv
outcom
singl
prospect
random
mask
placebocontrol
trial
dog
cpv
enter
show
dog
treat
oseltamivir
mgkg
po
signific
drop
white
blood
cell
count
wherea
untreat
dog
signific
drop
white
blood
cell
count
first
day
hospit
treat
dog
also
gain
weight
hospit
wherea
untreat
dog
lost
weight
howev
differ
hospit
time
treatment
need
clinic
score
morbid
mortal
two
group
number
dog
group
small
signific
advers
drug
effect
observ
oseltamivir
administ
dilut
water
order
reduc
reaction
tast
drug
vomit
shortli
drug
administr
author
acknowledg
potenti
concern
relat
administr
oral
medic
dog
enter
variabl
drug
absorpt
cpv
neuraminidas
hypothes
oseltamivir
instead
may
act
neuraminidas
bacteria
normal
respons
secondari
bacteri
infect
cpv
enter
primarili
gastrointestin
tract
role
bacteri
neuraminidas
pathogenesi
enter
bacteri
infect
bacteri
transloc
unknown
bacteri
neuraminidas
enzym
may
play
role
biofilm
format
help
bacteria
invad
mucin
layer
respiratori
tract
suggest
gut
bacteria
may
use
neuraminidas
enzym
cleav
sialic
acid
residu
gastrointestin
epitheli
cell
expos
receptor
site
bacteri
adher
major
concern
relat
treatment
cpv
enter
oseltamivir
possibl
select
resist
mutant
among
influenza
virus
widespread
use
drug
occur
veterinari
clinic
given
restrict
use
drug
treatment
human
influenza
viru
infect
investig
requir
use
oseltamivir
recommend
treatment
cpv
enter
although
use
treatment
cat
toxic
nucleosid
analogu
ribavirin
shown
promis
vitro
treatment
canin
distemp
viru
cdv
infect
anoth
drug
eicar
also
shown
activ
cdv
vitro
treatment
measl
viru
close
relat
cdv
ribavirin
primarili
use
treat
hepat
c
viru
infect
human
pharmacokinet
toxic
ribavirin
eicar
dog
requir
studi
nelfinavir
proteas
inhibitor
use
treat
hiv
infect
also
limit
replic
sever
acut
respiratori
syndrom
sar
coronaviru
vitro
mode
action
coronavirus
poorli
understood
nelfinavir
effect
mous
model
sar
although
nelfinavir
alon
complet
effect
combin
nelfinavir
galanthu
nivali
agglutinin
gna
inhibit
replic
felin
coronaviru
vitro
may
applic
treatment
felin
infecti
periton
fip
gna
appear
bind
viral
outer
envelop
glycoprotein
prevent
cellular
entri
use
nelfinavir
report
cat
natur
occur
coronaviru
infect
toxic
pharmacokinet
nelfinavir
gma
cat
efficaci
drug
treatment
fip
remain
unknown
immunomodul
drug
alter
immun
system
function
immunomodul
also
refer
biolog
respons
modifi
use
treatment
infecti
diseas
may
benefici
compromis
immun
system
impair
effect
antimicrobi
drug
treatment
altern
immunomodul
use
dampen
excess
host
inflammatori
respons
varieti
immunomodul
use
treat
felin
retrovir
infect
fip
infect
canin
felin
parvovir
enter
tabl
immunomodul
use
veterinari
medicin
divid
six
main
group
microbi
product
plantderiv
biolog
respons
modifi
natur
occur
cytokin
colonystimul
factor
interferon
immunoglobulin
glucocorticoid
synthet
compound
immunomodulatori
activ
pentoxifyllin
treatment
canin
felin
viral
infect
immunomodul
frequent
associ
disappoint
result
data
larg
prospect
control
clinic
trial
gener
avail
frequent
immunomodul
show
antivir
activ
vitro
correl
treatment
respons
vivo
sometim
mild
moder
clinic
improv
observ
treatment
result
cure
use
human
recombin
cytokin
beyond
week
treatment
associ
develop
antibodi
cytokin
potenti
crossreact
endogen
cytokin
absenc
data
random
placebocontrol
clinic
trial
support
use
immunomodul
use
caution
may
potenti
acceler
diseas
may
occur
virus
depend
rapidli
divid
cell
replic
parvoviru
replic
activ
lymphocyt
fiv
promot
inflammatori
respons
may
also
detriment
effect
immunemedi
process
play
import
role
pathogenesi
diseas
fip
microbi
product
immunomodulatori
activ
includ
bacillu
extract
mycobacteri
cell
wall
extract
mycobacterium
bovi
purifi
staphylococc
protein
kill
propionibacterium
acn
immunoregulin
immunovet
staphylococcu
aureu
phage
lysat
staphag
lysat
delmont
laboratori
usa
serratia
marcescen
abstract
inactiv
poxvirus
baypamun
bayer
date
control
clinic
trial
product
demonstr
signific
efficaci
treatment
viral
infect
dog
cat
staphylococc
phage
lysat
contain
compon
aureu
bacteriophag
propionibacterium
acn
immunotherapi
shown
efficaci
treatment
pyoderma
dog
avail
commerci
purpos
see
tabl
also
see
chapter
acemannan
carrisyn
carrington
laboratori
irv
tx
mucopolysaccharid
deriv
alo
vera
plant
leav
induc
cytokin
product
dendrit
cell
matur
stimul
macrophag
secret
varieti
cytokin
includ
prostaglandin
use
treat
fiv
felv
infect
either
oral
parenter
administr
veterinari
product
avail
treatment
canin
felin
fibrosarcoma
control
trial
need
understand
efficaci
treatment
natur
infect
cat
polyprenyl
immunostimul
sass
sass
inc
oakridg
tn
plantderiv
investig
veterinari
biolog
made
phosphoryl
linear
polyisoprenol
vitro
upregul
synthesi
cytokin
antivir
properti
cat
experiment
induc
infect
decreas
sever
durat
upper
respiratori
tract
sign
treat
polyprenyl
immunostimul
comparison
placebotr
cat
longterm
year
surviv
report
cat
noneffus
fip
treat
polyprenyl
immunostimul
respons
cat
effus
fip
disappoint
colonystimul
factor
csf
natur
occur
glycoprotein
stimul
product
differenti
surviv
activ
white
blood
cell
exampl
includ
erythropoietin
thrombopoietin
stimul
eosinophil
basophil
product
stem
cell
factor
macrophag
csf
granulocyt
csf
gcsf
granulocytemacrophag
csf
gmcsf
recombin
gcsf
use
wide
veterinari
medicin
immunomodul
use
drug
may
limit
cost
immunogen
granulocyt
colonystimul
factor
granulocyt
csf
stimul
growth
differenti
neutrophil
cell
line
also
stimul
neutrophil
function
includ
chemotaxi
phagocytosi
antibodydepend
cellular
cytotox
superoxid
product
nonglycosyl
recombin
human
gcsf
avail
trade
name
neupogen
pegfilgrastim
neulasta
pegyl
form
long
halflif
singledos
administr
lenograstim
glycosyl
form
avail
outsid
unit
state
three
form
similar
efficaci
advers
effect
human
gcsf
approv
use
human
treatment
chemotherapyinduc
myelosuppress
treatment
sever
chronic
neutropenia
mobil
collect
peripher
blood
stem
cell
bone
marrow
transplant
acceler
myeloid
reconstitut
hematopoiet
stem
cell
transplant
gcsf
gmcsf
use
treat
pneumonia
sever
sepsi
human
without
neutropenia
signific
benefit
identifi
gcsf
administ
daili
subcutan
inject
dog
cat
neutrophil
count
increas
sever
day
result
enhanc
rate
granulopoiesi
shorten
neutrophil
matur
time
slight
increas
monocyt
lymphocyt
count
also
occur
count
return
normal
day
discontinu
treatment
veterinari
medicin
filgrastim
use
treat
chemotherapyinduc
neutropenia
cyclic
neutropenia
gray
colli
filgrastim
effect
treatment
leukopenia
experiment
induc
cpv
infect
repeat
administr
filgrastim
dog
cat
associ
develop
antibodi
protein
within
week
treatment
crossreact
endogen
gcsf
thu
although
increas
neutrophil
count
fivinfect
cat
longterm
use
filgrastim
recommend
recombin
canin
gcsf
rcgcsf
may
safer
longterm
use
dog
possibl
also
cat
one
recombin
canin
formul
mobil
neutrophil
dog
within
hour
administr
recombin
canin
gcsf
reduc
sever
durat
bone
marrow
suppress
induc
cyclophosphamid
dog
prospect
nonrandom
clinic
trial
treatment
cpv
infect
neutrophil
count
higher
hospit
time
shorter
dog
treat
rcgcsf
surviv
time
decreas
treatment
canin
felin
parvoviru
infect
gcsf
might
caus
harm
increas
cell
turnov
induc
drug
might
promot
parvoviru
replic
studi
requir
evalu
util
rcgcsf
treatment
neutropenia
associ
canin
parvovir
enter
felin
retroviru
infect
chronic
canin
monocyt
ehrlichiosi
dog
cat
exogen
gcsf
well
toler
human
patient
main
advers
effect
treatment
bone
musculoskelet
pain
headach
anemia
thrombocytopenia
splenomegali
longterm
use
human
associ
osteopenia
result
upregul
osteoclast
activ
rare
complic
peopl
includ
splenic
ruptur
exacerb
autoimmun
disord
granulocytemacrophag
colonystimul
factor
gmcsf
stimul
growth
function
neutrophil
monocyt
eosinophil
commerci
gmcsf
formul
avail
treatment
hematolog
disord
human
patient
includ
sargramostim
molgramostim
regramostim
vari
slightli
amino
acid
sequenc
degre
glycosyl
use
treat
cat
fiv
viral
load
increas
use
gmcsf
recommend
treatment
fivinduc
cytopenia
interestingli
sargramostim
use
treat
human
patient
aidsassoci
opportunist
infect
includ
oropharyng
candidiasi
dissemin
mycobacteri
infect
administr
recombin
human
gmcsf
dog
associ
antibodi
develop
day
interferon
cytokin
antivir
properti
type
interferon
produc
leukocyt
fibroblast
respons
viral
infect
type
interferon
activ
natur
killer
nk
cell
increas
express
major
histocompat
complex
mhc
class
molecul
antitumor
activ
type
ii
interferon
produc
lymphocyt
nk
cell
respons
antigen
stimul
play
critic
role
clearanc
intracellular
pathogen
macrophag
recombin
human
use
treat
chronic
granulomat
diseas
human
well
chronic
infect
caus
intracellular
bacteria
fungi
recombin
veterinari
prepar
avail
interferon
alpha
natur
occur
repres
group
molecul
vari
slightli
composit
inhibit
viral
nucleic
acid
protein
synthesi
varieti
recombin
human
natur
prepar
avail
includ
pegyl
form
prolong
biolog
halfliv
human
patient
use
conjunct
antivir
drug
treat
hepat
b
hepat
c
viru
infect
papillomaviru
infect
hivassoci
kaposi
sarcoma
gener
administ
week
recombin
human
administ
parenter
oral
cat
treatment
felin
retrovir
infect
felin
upper
respiratori
viral
infect
fip
inhibit
replic
felv
fiv
felin
coronaviru
vitro
unfortun
mix
result
obtain
parenter
oral
administr
cat
retroviru
infect
parenter
effect
treatment
fip
parenter
administr
lead
develop
neutral
antibodi
appar
loss
activ
week
oral
administr
low
dose
treat
viral
infect
anim
controversi
proteolyt
degrad
gastric
acid
nevertheless
benefici
outcom
report
cat
felv
fiv
infect
presum
immunomodul
follow
mucos
absorpt
drug
topic
applic
eye
use
treat
kerat
control
studi
use
treatment
lack
avail
effect
antivir
drug
famciclovir
like
use
antivir
drug
may
take
preced
use
combin
treatment
feron
close
relat
secret
virusinfect
leukocyt
precis
mechan
action
known
dog
increas
macrophag
nk
cell
activ
antivir
activ
sever
felin
virus
vitro
includ
felv
felin
caliciviru
fcv
canin
felin
parvovirus
felin
coronaviru
also
antitumor
activ
recombin
felin
formul
produc
silkworm
avail
europ
canada
veterinari
use
virbagen
omega
virbac
similar
activ
canin
felin
cell
potenti
treatment
canin
felin
viral
infect
optim
dose
regimen
unknown
manufactur
recommend
three
cycl
treatment
day
consecut
day
preliminari
data
suggest
treatment
cat
fip
might
increas
surviv
time
random
placebocontrol
studi
natur
infect
cat
demonstr
improv
qualiti
life
surviv
time
cat
natur
occur
felvrel
diseas
treat
placebocontrol
trial
surviv
time
followup
period
increas
improv
clinic
score
laboratori
paramet
also
document
sick
cat
natur
infect
felv
fiv
despit
signific
chang
viral
load
drug
also
use
topic
oral
parenter
treat
infect
subcutan
treat
refractori
fcvassoci
stomat
oromucos
administr
cat
refractori
fcvassoci
stomat
led
signific
clinic
improv
compar
placebo
treatment
puppi
natur
experiment
induc
cpv
enter
number
placebocontrol
trial
associ
reduc
diseas
sever
studi
significantli
reduc
mortal
contrast
improv
surviv
cat
catteri
felin
panleukopenia
viru
infect
treat
compar
untreat
control
group
recombin
well
toler
dog
cat
transient
lethargi
fever
vomit
mild
diarrhea
anorexia
document
treat
cat
especi
higher
dose
ukg
mild
neutropenia
eosinophilia
revers
increas
activ
serum
ast
also
describ
follow
treatment
addit
studi
efficaci
safeti
larger
number
sick
cat
retrovir
infect
cat
dog
viral
infect
requir
lymphocyt
tcell
immunomodul
tcyte
therapeut
inc
protein
deriv
thymu
epitheli
cell
accord
product
brochur
ltci
upregul
product
vitro
regul
tcell
function
also
report
stimul
platelet
product
mice
chemotherapyinduc
thrombocytopenia
ltci
condit
approv
us
depart
agricultur
aid
treatment
fiv
felv
infect
associ
sign
cytopenia
opportunist
infect
control
independ
studi
efficaci
ltci
cat
requir
human
patient
human
intraven
immun
globulin
ivig
use
treatment
immunodefici
well
autoimmun
disord
figur
singl
infus
human
ivig
use
success
treat
immunemedi
thrombocytopenia
dog
repeat
administr
anim
may
lead
transfus
reaction
intraven
immunoglobulin
prepar
commerci
avail
passiv
immun
cat
dog
europ
contain
antibodi
fpv
fcv
feliserin
idt
biologika
gmbh
rodelben
germani
cdv
canin
adenoviru
cpv
stagloban
idt
biologika
gmbh
efficaci
prepar
report
subcutan
intraperiton
administr
adult
cat
serum
kitten
failur
passiv
transfer
provid
igg
concentr
equival
kitten
suckl
normal
gener
given
parenter
high
dose
specif
immunoglobulin
effect
prevent
treatment
infecti
diseas
oral
administr
effect
passiv
administr
antitoxin
also
use
treat
tetanu
see
chapter
neutral
snake
venom
compon
passiv
immun
may
associ
allerg
reaction
sever
potenti
interfer
subsequ
activ
immun
attempt
administ
antibodi
gener
elimin
period
week
bovin
lactoferrin
glycoprotein
immunomodulatori
properti
normal
present
exocrin
secret
neutrophil
reduc
cytokin
secret
mononuclear
cell
lymphocyt
activ
cat
infect
fiv
vitro
bovin
lactoferrin
antivir
activ
fcv
topic
applic
mgkg
day
mouth
small
number
fivposit
fivneg
cat
stomat
associ
improv
appetit
reduc
oral
inflamm
saliv
pain
increas
neutrophil
phagocyt
activ
chronic
oral
administr
bovin
lactoferrin
dog
integrinrel
neutrophil
dysfunct
associ
increas
neutrophil
function
recoveri
opportunist
infect
anim
human
infecti
diseas
treatment
glucocorticoid
sometim
use
dampen
overzeal
immun
respons
contribut
patholog
infect
glucocorticoid
potent
antiinflammatori
immunosuppress
properti
suppress
cytokin
synthesi
decreas
antibodi
product
caus
lymphocytolysi
eosinopenia
decreas
neutrophil
margin
interfer
reduc
activ
phospholipas
thu
initi
arachidon
acid
cascad
howev
glucocorticoid
administr
also
potenti
worsen
outcom
excess
immun
suppress
use
advoc
specif
infecti
diseas
certain
circumst
glucocorticoid
also
contribut
develop
secondari
infect
even
use
treat
anoth
diseas
exampl
unusu
dog
cat
latent
infect
emerg
secondari
infect
develop
eg
demodicosi
staphylococc
pyoderma
dermatophytosi
system
mycos
glucocorticoid
use
produc
immunosuppress
exampl
benefici
effect
glucocorticoid
treatment
infecti
diseas
fip
inflamm
play
major
role
pathogenesi
although
control
clinic
trial
compar
prednison
treatment
placebo
perform
mani
cat
treatment
prednisolon
mgkg
po
associ
transient
complet
partial
remiss
result
gener
accept
standard
care
treatment
fip
see
chapter
short
cours
prednisolon
use
immunosuppress
dose
mgkg
po
also
use
suppress
secondari
immunemedi
hemolysi
cat
infect
mycoplasma
haemof
given
glucocorticoid
reactiv
hemoplasma
infect
addit
studi
need
determin
whether
practic
improv
outcom
similarli
glucocorticoid
treatment
use
suppress
immunemedi
consequ
infect
tickborn
pathogen
ehrlichia
cani
babesia
spp
antimicrobi
treatment
alon
follow
complet
resolut
clinic
abnorm
adjunct
glucocorticoid
treatment
worsen
outcom
dog
rocki
mountain
spot
fever
contrast
glucocorticoid
administr
may
neg
impact
dog
lyme
arthriti
anecdot
report
improv
outcom
dog
suspect
lyme
glomerulonephr
treat
methylprednisolon
sodium
succin
conjunct
immunosuppress
drug
mycophenol
mofetil
azathioprin
see
chapter
mani
larg
human
studi
assess
role
glucocorticoid
treatment
septic
shock
see
chapter
treatment
high
dose
hydrocortison
less
day
contraind
secondari
infect
gastrointestin
bleed
treatment
physiolog
dose
glucocorticoid
advoc
overcom
rel
adren
insuffici
occur
sever
septic
shock
human
dog
recent
consensu
guidelin
human
patient
septic
shock
recommend
adjunct
hydrocortison
treatment
patient
unrespons
fluid
resuscit
treatment
vasopressor
infect
gener
inflamm
within
eye
cn
frequent
treat
antiinflammatori
dose
topic
system
glucocorticoid
respect
conjunct
antimicrobi
drug
goal
treatment
minim
prevent
loss
vision
deterior
neurolog
statu
especi
organ
death
follow
profound
inflammatori
respons
cn
infect
effect
concurr
glucocorticoid
treatment
may
depend
specif
pathogen
present
immun
respons
infect
individu
prospect
studi
evalu
outcom
adjunct
glucocorticoid
treatment
cn
infect
dog
cat
lack
retrospect
studi
treatment
dog
cat
cn
cryptococcosi
antiinflammatori
dose
glucocorticoid
increas
surviv
first
day
start
antifung
drug
treatment
pentoxifyllin
synthet
methylxanthin
deriv
theobromin
broadspectrum
phosphodiesteras
inhibitor
varieti
immunomodulatori
properti
rodent
human
inhibit
product
well
activ
b
cell
increas
neutrophil
mobil
chemotaxi
increas
erythrocyt
camp
level
result
increas
erythrocyt
deform
lower
blood
viscos
improv
microcircul
tissu
perfus
pentoxifyllin
also
decreas
platelet
aggreg
increas
tissu
plasminogen
activ
patient
hyperaggreg
platelet
may
use
treatment
disord
result
hypercoagul
state
valu
pentoxifyllin
treatment
endotoxemia
primarili
studi
hors
despit
signific
decreas
tnf
activ
incub
equin
monocyt
pentoxifyllin
vitro
effect
occur
hors
vivo
benefici
effect
pentoxifyllin
limit
hors
administ
iv
challeng
endotoxin
dog
pentoxifyllin
use
treat
varieti
skin
diseas
includ
canin
atop
dermat
dermatomyos
cutan
vasculopathi
cat
use
treat
fip
mask
placebocontrol
studi
relat
drug
propentofyllin
show
benefit
treatment
dog
pentoxifyllin
low
unpredict
oral
bioavail
short
halflif
threetimesdaili
administr
recommend
advers
effect
includ
vomit
decreas
appetit
like
occur
tablet
crush
crush
tablet
also
unpalat
cat
antimicrobi
drug
immunomodulatori
properti
includ
macrolid
doxycyclin
metronidazol
mechan
activ
discuss
chapter
magg
dj
antivir
therapi
felin
herpesviru
infect
vet
clin
north
small
anim
pract
